- Home
- STSS vs SNPX Comparison
STSS vs SNPX Comparison
Compare STSS & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- SNPX
- Stock Information
- Founded
- STSS 2017
- SNPX 2012
- Country
- STSS United States
- SNPX United States
- Employees
- STSS N/A
- SNPX N/A
- Industry
- STSS Medical/Dental Instruments
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- STSS Health Care
- SNPX Health Care
- Exchange
- STSS Nasdaq
- SNPX Nasdaq
- Market Cap
- STSS 3.3M
- SNPX 3.1M
- IPO Year
- STSS 2022
- SNPX N/A
- Fundamental
- Price
- STSS $0.02
- SNPX $2.33
- Analyst Decision
- STSS
- SNPX Strong Buy
- Analyst Count
- STSS 0
- SNPX 1
- Target Price
- STSS N/A
- SNPX $14.00
- AVG Volume (30 Days)
- STSS 282.3M
- SNPX 11.5K
- Earning Date
- STSS 05-13-2025
- SNPX 05-14-2025
- Dividend Yield
- STSS N/A
- SNPX N/A
- EPS Growth
- STSS N/A
- SNPX N/A
- EPS
- STSS N/A
- SNPX N/A
- Revenue
- STSS N/A
- SNPX N/A
- Revenue This Year
- STSS N/A
- SNPX N/A
- Revenue Next Year
- STSS N/A
- SNPX N/A
- P/E Ratio
- STSS N/A
- SNPX N/A
- Revenue Growth
- STSS N/A
- SNPX N/A
- 52 Week Low
- STSS $0.01
- SNPX $1.84
- 52 Week High
- STSS $18.15
- SNPX $5.38
- Technical
- Relative Strength Index (RSI)
- STSS 29.62
- SNPX 49.26
- Support Level
- STSS $0.02
- SNPX $2.05
- Resistance Level
- STSS $0.04
- SNPX $2.21
- Average True Range (ATR)
- STSS 0.01
- SNPX 0.18
- MACD
- STSS 0.02
- SNPX 0.04
- Stochastic Oscillator
- STSS 22.20
- SNPX 79.51
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes are designed to eliminate potentially infectious and accidental needlestick injuries.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.